PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready

Since a U.S. circuit court decided the First Amendment protected a pharma sales rep from off-label marketing charges, the free-speech arguments have multiplied in cases across the country, testing that Second Circuit decision in other regions.

Allergan sets date for special meeting but vows to keep fighting Valeant buyout

Put it on the calendar: Allergan has scheduled its special shareholder meeting–key to Valeant's takeover attempt–for Dec. 18. But that doesn't mean it won't continue to fight the very idea in court.

Black box warning for antidepressants spelled the death of litigation

There used to be a legal specialty built by plaintiff attorneys around filing lawsuits against antidepressant makers and then settling them. But the black box warning put on antidepressants in 2004 has turned out to be a shroud for the once lucrative legal business.

Novartis CEO Jimenez shrugs off biosimilars in the short term

Swiss drugmaker Novartis last month became the first drugmaker to present the FDA with an application for a biosimilar, kicking off a new era in the U.S. that many believe will be a game changer for the industry. But from where CEO Joe Jimenez sits, it looks like no big deal for now.

Looking for a Xalkori boost, Pfizer adds targeted med to Merck IO pact

Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them–Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.

Valeant’s deal show goes on with $25M dermatology buy

Even a heated takeover battle replete with litigation, a media war, and plenty of name-calling can't grind the Valeant M&A engine to a halt. The company has resumed its skincare buying spree, picking up a dermatology portfolio and an array of specialty products from Valeo Pharma for $25.3 million.

China’s Luye Pharma founder soars into pharma’s billionaire echelon

China's pharma corruption crackdown hasn't helped multinationals' top lines, which only recently began returning to normal after taking a hit last fall. But it may be opening up an opportunity for domestic drugmakers and their owners–like new Billionaire Club member Liu Dian Bo–to make a splash.

Galena says goodbye to ex-CEO, no severance pay included

Galena Biopharma announced a new CEO last week. The outgoing chief, Mark Ahn, was said to be leaving to pursue "other long-held personal and professional goals." That's an obvious red flag: Ahn must have been not-so-gently reminded that he had other long-held goals.

Celebrity pitch-folks may not be worth the money, study finds

Celebrities are making more and more appearances in pharma's DTC advertising. But do they help meds score with patients the same way they help sell consumer goods?

Jumping into global M&A mix key to India growing its pharma industry

India's drug business has taken a big financial hit in the last years as the FDA has stopped some of its top players from shipping drugs to the U.S. But experts still sees big potential in the industry, saying it will grow faster than other Indian industries, particularly if players shed their conservative approach and get involved in the global M&A mix that their larger competitors are benefiting from.

View sitemap

ob_end_flush();